Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant mouse monoclonal antibody expressed in Sp2/0 mouse myeloma cells binding to human EpCAM/17-1A. Edrecolomab is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM/17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma. However, when put to a phase III study it did not provide any benefit when compared to conventional chemotherapeutic agents. Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.
IgG2a - kappa
The details of the immunogen for this antibody are not available.
Sp2/0 mouse myeloma cells
Suitable for use in ELISA, IP, FC, FuncS, IF, Neut and most other immunological methods.
Approximately 150 kDa
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.
Edrecolomab is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM/17-1A.
This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy.